Trial · NCT07406685
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
NCT07406685, Phase 4, Recruiting, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation. Trials, record NCT07406685. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07406685
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
- NCT number
- NCT07406685
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 52 participants, estimated
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis, Osteoporosis
- Interventions
- Ibandronate IV, Zoledronic acid IV
- First posted
- 2026-02-12
- Last updated
- 2026-08-25
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change in bone mineral density (BMD) | Baseline to 24 months after treatment initiation. | Change in BMD at the lumbar spine, femoral neck, and total hip measured by dual-energy X-ray absorptiometry (DXA) from baseline to 24 months. Baseline is defined as the time point 6 months after the last dose of denosumab, immediately prior to initiation of sequential therapy. BMD measurements will be performed at 6, 12, 18, and 24 months after treatment initiation. |
| Secondary | Change in bone turnover makers (BTM) level | Baseline to 24 months | Changes in serum bone turnover markers, including procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide of type I collagen (CTX), will be evaluated to assess bone metabolic activity following denosumab discontinuation and sequential therapy. Measurements will be obtained at baseline and at 3, 6, 9, 12, 18, and 24 months after treatment initiation. |
| Secondary | Change in visual Analogue Scale (VAS) score | Baseline to 24 months | The Visual Analogue Scale (VAS) for pain will be used to assess participants' self-reported pain intensity. The VAS score ranges from 0 to 10, higher scores indicate worse pain intensity, and lower scores indicate less pain. Pain intensity of the lower back and lower extremities will be evaluated at baseline and every 6 months during follow-up. |
| Secondary | Incidence of osteoporotic fractures | During the intervention period, up to 24 months. | The occurrence and anatomical sites of osteoporotic fractures will be recorded throughout the study period. |
| Secondary | Incidence of adverse events (AEs) and serious adverse events (SAEs) | During the intervention period, up to 24 months. | All AEs and SAEs will be recorded and evaluated throughout the study period to assess the safety of sequential therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07406685
GET https://conductscience.org/api/trials/v1/NCT07406685/papers?page=2